gms | German Medical Science

68th Annual Meeting of the German Society of Neurosurgery (DGNC)
7th Joint Meeting with the British Neurosurgical Society (SBNS)

German Society of Neurosurgery (DGNC)

14 - 17 May 2017, Magdeburg

Article

Send article

Systematic analysis of anti-estrogen effects in pituitary adenoma cells

Meeting Abstract

Search Medline for

  • Marcella Steffani - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Benjamin Voellger - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Junwen Wang - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Jörg-Walter Bartsch - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland
  • Christopher Nimsky - Klinik für Neurochirurgie, Universität Marburg, Marburg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. Society of British Neurological Surgeons. 68. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), 7. Joint Meeting mit der Society of British Neurological Surgeons (SBNS). Magdeburg, 14.-17.05.2017. Düsseldorf: German Medical Science GMS Publishing House; 2017. DocMO.28.08

doi: 10.3205/17dgnc176, urn:nbn:de:0183-17dgnc1760

Published: June 9, 2017

© 2017 Steffani et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: Interfering with the estrogen receptor alpha pathway appears an attractive way to eliminate tumor cells in pituitary adenomas. Here we attempted to assess the potency of several anti-estrogens on cell viability in rodent pituitary adenoma cells.

Methods: TtT-GF and GH3 cells were incubated with Bazedoxifene, Clomiphen, Fulvestrant, Raloxifene, and Tamoxifen in a submicromolar to high micromolar concentration range for up to five days. Cell viability was assessed using either a water soluble tetrazolium (WST)-1 assay or 4',6-diamidino-2-phenylindole (DAPI) staining. Half-maximal inhibitory concentrations (IC50) of anti-estrogens were calculated based on three independent experiments performed in triplicates.

Results: After five days, viability of TtT-GF cells was significantly decreased by Bazedoxifene (IC50=35µM, p=0.0044), Clomiphen (IC50=5µM, p<0.0001), and Raloxifene (IC50=20µM, p=0.013), while Fulvestrant did not show a significant effect on TtT-GF cell viability even at high micromolar concentrations. Similarly, after five days, viability of GH3 cells was significantly decreased by Bazedoxifene (IC50=20µM, p=0.013), Clomiphen (IC50=15µM, p=0038), Fulvestrant (IC50=1µM, p<0.022), and Raloxifene (IC50=35µM, p=0.031).

Conclusion: Viability of TtT-GF and GH3 cells was selectively decreased by anti-estrogens, of which Clomiphen had the highest potency in both cell lines. Further investigation of anti-estrogens in human cell lines is warranted to evaluate the clinical potential of anti-estrogens in pituitary adenomas.